The FDA approved a once-monthly, single-injection regimen for Omvoh, enhancing convenience for UC patients. Omvoh, an IL-23p19 antagonist, offers bioequivalent efficacy to the previous two-injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results